prostatic cancer
Conditions
Interventions
one-armed:Utidelone
Sponsors
Cancer Center, Sun Yat-sen University
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The subjects voluntarily joined the study and signed the informed consent; 2. Aged 18 - 75 years at the date of signature of the informed consent; 3. Patients with histologically or cytologically proven adenocarcinoma of the prostate, excluding small cell carcinoma or other specific types of prostate cancer (non-acinar cell carcinoma); 4. Progression of disease after standard treatment (according to the Prostate Cancer Clinical Trial Working Group 3 criteria), patients must be considered for metastatic castration-resistant prostate cancer (mCRPC) for at least one third-generation antiandrogen (e.g. abiraterone or anthracelul) and docetaxel treatment failure or unsuitable for docetaxel treatment; 5. ECOG score of 0~2; 6. The expected survival >= 3 months.
Exclusion criteria
Exclusion criteria: 1. Had received epomycin within 1 year before administration of the study drug; 2. Severe allergic to epomycin; 3. Patients with grade 3 or above peripheral neurotoxicity during previous chemotherapy; 4. Currently receiving other anti-tumor therapy; 5. Clinically significant mental or central nervous system disorders; 6. Brain metastases with clinical symptoms; 7. Major surgery, or radiotherapy, within 28 days prior to study initiation, or elective surgery required during the study period; 8. Received Chinese herbal or proprietary medicine treatment within 7 days prior to the start of study treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA remission rate; | — |
Countries
China
Contacts
Public ContactShi Yanxia
Cancer Center, Sun Yat-sen University
Outcome results
None listed